Clinical Trials Market

Clinical Trials Market by Phase (Phase I, II, III), Service Type (Laboratory, Analytical Testing, Patient Recruitment, Protocol Designing), Therapeutic Area (Oncology, Cardiology, Neurology), and Application (Vaccine, mAbs, CGT) - Global Forecast to 2028

Report Code: PH 1622 Sep, 2023, by marketsandmarkets.com

The global clinical trials market in terms of revenue was estimated to be worth $48.2 billion in 2023 and is poised to reach $73.2 billion by 2028, growing at a CAGR of 8.7% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by the increasing number of clinical trials, increasing drugs in the pipeline, and rising investment in pharmaceutical R&D. On the other hand, the shortage of skilled professionals for clinical trials is a major factor expected to pose a challenge to the growth of this market.

Attractive Opportunities in the Clinical Trials Market

Clinical Trials Market

To know about the assumptions considered for the study, Request for Free Sample Report

Clinical Trials Market

Global Clinical Trials Market Dynamics

DRIVER: Increasing drugs in the pipeline and rising investments in pharmaceutical R&D

Pharmaceutical, biopharmaceutical, and medical device companies are significant investors in the development of innovative drugs and devices. This industry is highly R&D intensive, with a focus on delivering both high-quality and novel products. Recent trends reveal that leading pharmaceutical companies are enhancing R&D efficiencies by making substantial R&D investments for long-term returns and fostering collaborative research activities. The rising R&D investments within the pharmaceutical and biopharmaceutical sectors are driving a shift towards comprehensive integrated or functionally outsourced services encompassing the entire process of drug discovery and development, starting from early-stage development to late-stage development phase. To enhance profitability, meet stringent drug development timelines, and achieve cost efficiencies, a significant number of pharmaceutical and biopharmaceutical companies now outsource their testing functions during R&D to CROs. This inclination is notably evident in recent partnerships between prominent pharmaceutical firms and Contract Research Organizations (CROs). Furthermore, advancements in biotechnology have resulted in a sharp increase in drug candidates in the pipeline. For instance, the number of drug candidates in the development pipeline has increased from 10,479 in 2013 to 17,737 by 2020. Projections indicate a continuation of this trend, with an estimated count of 21,292 drug candidates anticipated by the end of the year 2023. These trends are expected to drive the market during the forecast period.

Restraint: Need for unique testing approaches for innovative molecules

The pharmaceutical and biopharmaceutical industries have witnessed a considerable rise in competitiveness as they strive to create novel treatments and secure patent exclusivity through accelerated drug development. Bioanalytical testing plays a critical role across all stages of pharmaceutical and biopharmaceutical development and stands as the most frequently outsourced process within the scope of chemistry, manufacturing, and control (CMC) activities. CMC data also holds essential significance in meeting regulatory expectations and attaining approval for Investigational New Drug (IND) applications. The variety of requirements in chemistry, manufacturing, and control (CMC) for seeking approval for biopharmaceutical Investigational New Drug (IND) and developing innovative drug delivery systems presents different challenges. These challenges impose the use of novel and innovative analytical methods to test the new drug molecules.

OPPORTUNITY: Favorable outlook for biologics and biosimilars

The field of pharmaceuticals and biotechnology has experienced rapid expansion in recent times. Notable investments have been seen in R&D activities aimed at creating innovative medications and biological substances for tackling a range of illnesses. Many new drugs and biologics are currently in the clinical trial stages of development. s. With the continuous influx of novel pharmaceutical products in the pipeline, the demand for clinical trial services is expected to witness substantial growth. Despite an overall reduction in approvals by the US FDA in 2022 due to the COVID-19 impact, the biologics sector remained unaffected, recording the approval for 15 new molecules and maintaining momentum from prior years. As in previous years, cancer continued to be the condition most addressed by monoclonal antibodies, which also continued to be the medicine class with the most approvals.

CHALLENGE: Shortage of Skilled Professionals in Clinical Trials

Clinical research organizations (CROs) are facing a tough time finding and keeping skilled people. They're competing with drug companies, biotech firms, medical device makers, and academic research institutes for qualified and experienced scientists. To compete effectively, these companies have to offer better pay and perks. But this can affect their financials and results, especially for small-scale clinical trials service providers. This shortage of skilled professionals may hamper the adoption of new technologies and methodologies and inhibit the growth of the market in the coming years.

According to the Global Workforce Intelligence (GWI) Project, by 2025, there will be a staggering demand-supply gap of 2.1 million healthcare workers, with one in three roles remaining unfilled. Per CareerBuilder, only 5.7 million people were available for recruitment in the US in September 2022, despite the 6.6 million clinical research positions offered. Additionally, seven positions are listed for every CRC searching for employment.

Even though small-molecule drugs dominate the global pharmaceutical market, the share of biologics, biosimilars, and large-molecule drugs is growing, led by the launch of new biologic-based drugs and increased revenues from existing biologics. Biologics and biosimilars require more specialty testing services such as biomarker testing and virology testing at each stage than small molecules. The increasing need for outsourcing these services to CROs is expected to stimulate the growth of the market in the coming years.

Clinical Trials Market Ecosystem

The global clinical trials market ecosystem includes raw material suppliers, clinical trials service providers, and end users such as pharmaceutical & biotechnology companies, medical device companies, and academic institutes. Raw material suppliers and service providers offer supplies and services for Phase I to Phase IV clinical trials and other studies. This includes consumables, assays, kits, accessories, and other products required throughout drug development.

Clinical research entities partner with their clients (such as pharmaceutical and biotechnology companies) to design strategies, implement them, and manage services. This long-term relationship enables the partners to conduct trials successfully and bring new products to market. Also, as the partners work together for a long time, the contracted work volume can expand, depending on how comfortable they are in taking their partnership forward.

Clinical Trials Market Ecosystem

The laboratory services segment dominated the clinical trials industry by service type.

The laboratory services segment held the largest share of the global clinical trials market in 2022. The increasing importance of laboratory services to establish regulatory compliance is expected to boost the growth of the segment during the forecast period. Laboratory services play a crucial role across every phase of drug development, encompassing clinical advancement. These services act as a basis for pharmaceutical, biopharmaceutical, and medical device enterprises, supporting them in adhering to regulatory benchmarks and ensuring the production of high-quality products. Furthermore, the increasing number of CROs providing a comprehensive range of laboratory services is expected to drive the segment growth.

The phase III segment accounted for the largest share of the clinical trials industry in 2022 by Phase.

The phase III segment accounted for the major share of the global clinical trials market in 2022. Additionally, the segment is expected to grow at a higher CAGR during the forecast. Factors such as large patient population for the clinical study as compared to other phases and utilization of sophisticated services to study the safety and efficacy of the drug candidates have contributed to the growth of this segment. Additionally, phase III clinical trials are considered complex clinical trials that require both robust technologies and reliable clinical resources to recruit patients efficiently, initiate sites quickly, and provide cost-effective study management. Most pharmaceutical, biopharmaceutical, and medical device manufacturers outsource services for Phase III clinical trials to CROs; this has contributed to the largest market share of the segment in the global market.

The Cardiology segment of the clinical trials industry is projected to register a higher growth rate during the forecast period by therapeutic area.

The cardiology segment of the clinical trials market is expected to grow at a higher CAGR during the forecast period. The growth of this segment is attributed to the high prevalence of cardiovascular diseases, the rising geriatric population, and the increasing number of partnerships between clinical trial service providers and pharmaceutical & biotechnology companies. Cardiovascular diseases (CVDs) are one of the leading causes of death worldwide. According to a report published by the World Heart Federation, Cardiovascular illnesses continue to impact more than half a billion people worldwide and were responsible for 20.5 million deaths in 2021, or close to a third of all deaths worldwide, and a rise from the anticipated 121 million CVD fatalities. This has created a demand for advanced cardiology drugs, which in turn drive the adoption of clinical trial services for the same.

Asia Pacific region of the clinical trials industry is estimated to register the highest CAGR during the forecast period.

Asia Pacific offers lucrative growth potential for the clinical trials market. This can be attributed to the growing pharmaceutical industry, implementation of favorable government policies, increasing number of newly established manufacturing facilities, and the low cost of clinical trials in the region.

Additionally, The APAC market is also becoming a major drug development and clinical research destination. The expansion of clinical trial operations in the region is mostly attributed to cost benefits, a sizable treatment population, participant retention in clinical trials, and ongoing regulatory procedural improvements. These benefits have caused the majority of pharmaceutical, biopharmaceutical, and medical device businesses to outsource their clinical trial efforts to CROs in this industry. Rapid growth in the outsourcing of preclinical, clinical, and laboratory testing services to Asia Pacific countries is expected to significantly drive market growth during the forecast period.

Clinical Trials Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the clinical trials market include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Syneos Health (US), WuXi AppTec (China), Charles River Laboratories (US), Parexel International  Corporation (US), Thermo Fisher Scientific Inc. (US), ICON plc (Ireland), Medpace (US), ACM Global Laboratories (US), Advanced Clinical (US), SGS (Switzerland), Frontage Labs (US), PSI (Switzerland), Bioagile (India), Fortrea Inc. (US), Clinical Trial Service (Netherlands), Worldwide Clinical Trials (US), Pepgra (UK), CTI Clinical Trial & Consulting (US), Dove Quality Solutions (UK), Firma Clinical Research (US), Celerion (US), Novotech (Australia), and Linical Americas (Japan).

Scope of the Clinical Trials Industry:

Report Metric

Details

Market Revenue in 2023

$48.2 billion

Estimated Value by 2028

$73.2 billion

Revenue Rate

Poised to grow at a CAGR of 8.7%

Market Driver

Increasing drugs in the pipeline and rising investments in pharmaceutical R&D

Market Opportunity

Favorable outlook for biologics and biosimilars

This report categorizes the Clinical trials market to forecast revenue and analyze trends in each of the following submarkets:

By Phase

  • Phase III
  • Phase II
  • Phase IV
  • Phase

By Service Type

  • Laboratory Services
  • Bioanalytical Testing Services
    • Cell-Based Assay
    • Virology Testing
    • Serology, Immunogenicity, & Neutralizing Antibodies
    • PK/PD Testing
    • Method Development, Optimization & Validation
    • Biomarker Testing
    • Other Bioanalytical Testing Services
  • Decentralized Clinical Trial Services
  • Patient Recruitment
  • Site Identification
  • Analytical Testing Services
  • Clinical Trial Supply & Logistic Services
  • Protocol Designing
  • Clinical Trial Data Management Services
  • Medical Device Testing Services
  • Other Services

By Therapeutic Area

  • Oncology
  • Infectious Diseases
  • Neurology
  • Metabolic Disorders
  • Immunology
  • Cardiology
  • Genetic Diseases
  • Women's Health
  • Other Therapeutic Areas

By Application

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Recent Developments of Clinical Trials Industry

  • In March 2023, Syneos Health entered into a multiyear agreement with Microsoft to create a platform that uses machine learning to elevate biopharma companies’ commercial performance and speed up clinical trial analysis, planning, and operation.
  • In September 2022, Parexel International established a new clinical trial supplies and logistics facility in Suzhou, China. This facility provides both local and international biopharmaceutical clients with quick access to clinical trial materials and medications for sites and patients, thus expediting the progress of clinical trials in the region.
  • In April 2021, CRL and Valence Discovery entered an alliance to provide AI-enabled drug design capabilities. The partnership will grant access to Valence’s ML platform.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 40)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 LIMITATIONS 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 44)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
          FIGURE 5 ILLUSTRATIVE EXAMPLE OF IQVIA: REVENUE SHARE ANALYSIS, 2022
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, THERAPEUTIC AREA, AND APPLICATION)
                    FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
           2.2.3 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, AND THERAPEUTIC AREA)
    2.3 GROWTH FORECAST 
          FIGURE 8 MARKET: CAGR PROJECTIONS, 2023–2028
          FIGURE 9 CLINICAL TRIALS INDUSTRY: GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 MARKET: RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 57)
    FIGURE 11 CLINICAL TRIALS MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028  (USD MILLION)
    FIGURE 13 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY SERVICE TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS INDUSTRY
 
4 PREMIUM INSIGHTS (Page No. - 61)
    4.1 CLINICAL TRIALS MARKET OVERVIEW 
          FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
    4.2 NORTH AMERICA: MARKET SHARE,  BY PHASE & COUNTRY (2022) 
          FIGURE 17 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 BIOANALYTICAL SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 
          FIGURE 18 CELL-BASED ASSAYS TO DOMINATE MARKET TILL 2028
    4.4 MARKET SHARE, BY THERAPEUTIC AREA,  2023-2028 
          FIGURE 19 ONCOLOGY TO HOLD LARGEST MARKET SHARE TILL 2028
    4.5 CLINICAL TRIALS INDUSTRY: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 65)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 CLINICAL TRIALS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing drugs in pipeline and rising investments in pharmaceutical R&D
                                FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028
                                FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2023
                    5.2.1.2 Increasing number of clinical trials
                                FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2022)
                    5.2.1.3 High cost of in-house drug development
                                FIGURE 25 DISTRIBUTION OF IN-HOUSE AND OUTSOURCING SERVICES EXPENDITURE IN GLOBAL PHARMA MARKET, 2014–2023 (% DISTRIBUTION)
                    5.2.1.4 Rising prevalence of orphan and rare diseases
                                FIGURE 26 OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023)
                                FIGURE 27 PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHES WITH ORPHAN DRUG DESIGNATION, 2012–2022
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Favorable outlook for biologics and biosimilars
                                FIGURE 28 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015–2022)
                                TABLE 5 LIST OF BIOLOGICS APPROVED BY US FDA, 2022
                                FIGURE 29 BIOSIMILAR APPROVALS AND LAUNCHES, 2015–2022
                    5.2.2.2 Rising demand for specialized testing services
                    5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
                                FIGURE 30 NUMBER OF ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (AS OF APRIL 2023)
                                FIGURE 31 GENE AND CELL THERAPY DEVELOPERS, CLINICAL TRIALS, AND INVESTMENTS,  BY REGION (AS OF 2022)
           5.2.3 CHALLENGES
                    5.2.3.1 Shortage of skilled professionals for clinical trials
                    5.2.3.2 Need for unique testing approaches for innovative molecules
           5.2.4 TRENDS
                    5.2.4.1 Adoption of AI-based tools for drug discovery
                    5.2.4.2 Increasing outsourcing activities in emerging Asian economies
                    5.2.4.3 Integrated end-to-end R&D service solutions
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 
          FIGURE 32 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 33 VALUE CHAIN ANALYSIS OF CLINICAL TRIALS
    5.5 INDICATIVE PRICING ANALYSIS 
          TABLE 6 PHASE 3 ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES)
          TABLE 7 PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN-EUROPE)
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 34 ECOSYSTEM ANALYSIS: MARKET
          TABLE 8 OVERALL MARKET ECOSYSTEM FOR CLINICAL TRIALS
    5.7 TECHNOLOGY ANALYSIS 
          FIGURE 35 IMPORTANCE OF TECHNOLOGY ADOPTION IN CLINICAL TRIALS
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 9 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 DEGREE OF COMPETITION
    5.9 REGULATORY ANALYSIS 
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 13 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 14 MARKET REGULATORY SCENARIO, BY COUNTRY/REGION
    5.10 KEY CONFERENCES AND EVENTS (2023–2024) 
           TABLE 15 CLINICAL TRIALS INDUSTRY: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024)
    5.11 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIALS
           5.11.2 BUYING CRITERIA FOR CLINICAL TRIALS
                     FIGURE 37 KEY BUYING CRITERIA FOR END USERS
 
6 CLINICAL TRIALS MARKET, BY PHASE (Page No. - 97)
    6.1 INTRODUCTION 
          TABLE 16 CLINICAL TRIALS INDUSTRY, BY PHASE, 2021–2028 (USD MILLION)
          FIGURE 38 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021 VS. 2022
    6.2 PHASE III CLINICAL TRIALS
           6.2.1 RISING PRICES OF PHASE III TRIALS TO DRIVE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES
                    TABLE 17 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE III (2021–2022)
                    TABLE 18 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 19 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 20 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.3 PHASE II CLINICAL TRIALS
           6.3.1 LONG DURATION OF PHASE II STUDIES TO PROVIDE GROWTH OPPORTUNITIES FOR CROS
                    TABLE 22 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE II (2021–2022)
                    TABLE 23 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 24 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 25 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.4 PHASE IV CLINICAL TRIALS
           6.4.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE MARKET
                    TABLE 27 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE IV (2021–2022)
                    TABLE 28 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 29 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 30 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 31 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.5 PHASE I CLINICAL TRIALS
           6.5.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES TO BOOST MARKET
                    TABLE 32 OVERVIEW OF DRUGS IN PHASE I STUDIES (2021–2022)
                    TABLE 33 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 34 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 35 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
 
7 CLINICAL TRIALS MARKET, BY SERVICE TYPE (Page No. - 109)
    7.1 INTRODUCTION 
           TABLE 37 CLINICAL TRIALS INDUSTRY, BY SERVICE TYPE, 2021–2028 (USD MILLION)
    7.2 LABORATORY SERVICES 
           7.2.1 RISING IMPORTANCE OF LAB SERVICES AND NEED TO ENSURE REGULATORY COMPLIANCE TO DRIVE MARKET
           TABLE 38 LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
           TABLE 39 LABORATORY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
           TABLE 40 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           TABLE 41 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           TABLE 42 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.3 BIOANALYTICAL TESTING SERVICES 
           TABLE 43 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
           TABLE 44 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
           TABLE 45 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           TABLE 46 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           TABLE 47 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           7.3.1 CELL-BASED ASSAYS
                    7.3.1.1 Rising number of providers offering customized assay testing to boost growth
                                TABLE 48 CELL-BASED ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 49 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 50 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 51 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.2 VIROLOGY TESTING
                    7.3.2.1 Rising uptake of in vitro virology assays to develop antiviral pharmaceuticals to favor market
                                TABLE 52 VIROLOGY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 53 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 54 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 55 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.3 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES
                    7.3.3.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to drive market
                                TABLE 56 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 57 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 58 EUROPE: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 59 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.4 PK/PD TESTING
                    7.3.4.1 Growing importance of drug pharmacokinetics to boost demand
                                TABLE 60 PK/PD TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 61 NORTH AMERICA: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 62 EUROPE: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 63 ASIA PACIFIC: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.5 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION
                    7.3.5.1 Biopharma industry preference for outsourcing method validation to drive market
                                TABLE 64 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 65 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 66 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 67 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.6 BIOMARKER TESTING
                    7.3.6.1 Growing emphasis on biomarker testing to develop personalized medicines and CDx to augment market
                                TABLE 68 BIOMARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 69 NORTH AMERICA: BIOMARKER TESTING MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 70 EUROPE: BIOMARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 71 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           7.3.7 OTHER BIOANALYTICAL TESTING SERVICES
                    TABLE 72 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 73 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 75 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.4 DECENTRALIZED CLINICAL TRIAL SERVICES 
           7.4.1 HIGH DEMAND FOR DCT ATTRIBUTED TO ADVANCEMENTS IN DIGITAL HEALTH TECHNOLOGIES
                    TABLE 76 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 77 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.5 PATIENT RECRUITMENT SERVICES 
           7.5.1 GROWING NEED FOR PATIENT-CENTRIC CLINICAL TRIAL SERVICES TO SUPPORT DEMAND
                    TABLE 80 OVERVIEW OF PATIENT RECRUITMENT SERVICE PROVIDERS
                    TABLE 81 PATIENT RECRUITMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 82 NORTH AMERICA: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 83 EUROPE: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 84 ASIA PACIFIC: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.6 SITE IDENTIFICATION SERVICES 
           7.6.1 INTRODUCTION OF DIGITAL TECHNOLOGIES ENABLING DATA VARIABILITY TO DRIVE MARKET
                    TABLE 85 SITE IDENTIFICATION SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 86 NORTH AMERICA: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 87 EUROPE: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 88 ASIA PACIFIC: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.7 ANALYTICAL TESTING SERVICES 
           7.7.1 INCREASING DEMAND FOR ANALYTICAL TESTING IN DRUG DEVELOPMENT TO DRIVE MARKET
                    TABLE 89 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 90 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 91 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 92 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.8 SUPPLY & LOGISTICS SERVICES 
           7.8.1 USAGE OF ADVANCED DATA ANALYTICS IN CLINICAL TRIAL SUPPLY MANAGEMENT TO DRIVE MARKET
                    TABLE 93 SUPPLY & LOGISTICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 94 NORTH AMERICA: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 95 EUROPE: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 96 ASIA PACIFIC: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.9 PROTOCOL DESIGNING SERVICES 
           7.9.1 NEED FOR PLANNING SUPPORT TO BOOST DEMAND FOR PROTOCOL DESIGN
                    TABLE 97 PROTOCOL DESIGNING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 98 NORTH AMERICA: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 99 EUROPE: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 100 ASIA PACIFIC: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.10 DATA MANAGEMENT SERVICES 
           7.10.1 DATA MANAGEMENT SERVICES TO RECORD HIGHEST CAGR OVER FORECAST PERIOD
                    TABLE 101 DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
                    TABLE 102 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 103 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 104 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 105 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.11 MEDICAL DEVICE TESTING SERVICES 
           7.11.1 INCREASING MEDICAL DEVICE R&D TO DRIVE MARKET
                    TABLE 106 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 107 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 108 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 109 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    7.12 OTHER SERVICES 
           TABLE 110 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
           TABLE 111 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           TABLE 112 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           TABLE 113 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
 
8 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA (Page No. - 148)
    8.1 INTRODUCTION 
          TABLE 114 CLINICAL TRIALS INDUSTRY, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
    8.2 ONCOLOGY 
           8.2.1 ONCOLOGY TO DOMINATE MARKET DUE TO RISING INCIDENCE OF CANCER
                    FIGURE 39 US CANCER INCIDENCE IN MALES, BY TYPE (2022)
                    FIGURE 40 US CANCER INCIDENCE IN FEMALES, BY TYPE (2022)
                    FIGURE 41 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010–2021 (THOUSAND)
                    TABLE 115 NEW FDA-APPROVED ONCOLOGY DRUGS (2023)
                    TABLE 116 CLINICAL TRIALS INDUSTRY FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 117 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 118 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 119 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    8.3 INFECTIOUS DISEASES 
           8.3.1 INFECTIOUS DISEASES TO HOLD SECOND-LARGEST MARKET SHARE, BY THERAPEUTIC AREA
                    TABLE 120 MARKET FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 121 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 122 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 123 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
    8.4 NEUROLOGY 
           8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET
                    TABLE 124 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
                    TABLE 125 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 126 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 127 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 128 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    8.5 METABOLIC DISORDERS 
           8.5.1 RISING DIABETES INCIDENCE TO DRIVE MARKET
                    FIGURE 42 INCREASE IN DIABETES CASES, 2000–2045 (MILLION INDIVIDUALS)
                    TABLE 129 CLINICAL TRIALS INDUSTRY FOR METABOLIC DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 130 NORTH AMERICA: MARKET FOR METABOLIC DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 131 EUROPE: MARKET FOR METABOLIC DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 132 ASIA PACIFIC: MARKET FOR METABOLIC DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
    8.6 IMMUNOLOGY 
           8.6.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS TO BOOST OUTSOURCING
                    TABLE 133 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
                    TABLE 134 MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 135 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 136 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 137 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    8.7 CARDIOLOGY 
           8.7.1 HIGH MORTALITY RATES TO DRIVE DEVELOPMENT OF NEW TREATMENTS
                    TABLE 138 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023)
                    TABLE 139 MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 140 NORTH AMERICA: MARKET FOR CARDIOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 141 EUROPE: MARKET FOR CARDIOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 142 ASIA PACIFIC: MARKET FOR CARDIOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    8.8 GENETIC DISEASES 
           8.8.1 GOVERNMENT SUPPORT FOR RARE & GENETIC DISEASE THERAPEUTICS TO BOOST MARKET
                    TABLE 143 CLINICAL TRIALS INDUSTRY FOR GENETIC DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 144 NORTH AMERICA: MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 145 EUROPE: MARKET FOR GENETIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 146 ASIA PACIFIC: MARKET FOR GENETIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
    8.9 WOMEN’S HEALTH 
           8.9.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL DEMAND
                    TABLE 147 MARKET FOR WOMEN’S HEALTH, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 148 NORTH AMERICA: MARKET FOR WOMEN’S HEALTH, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 149 EUROPE: MARKET FOR WOMEN’S HEALTH, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 150 ASIA PACIFIC: MARKET FOR WOMEN’S HEALTH, BY COUNTRY,  2021–2028 (USD MILLION)
    8.10 OTHER THERAPEUTIC AREAS 
          TABLE 151 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022)
          TABLE 152 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 153 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 154 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 155 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 CLINICAL TRIALS MARKET, BY APPLICATION (Page No. - 171)
    9.1 INTRODUCTION 
          TABLE 156 CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 SMALL MOLECULES 
           9.2.1 INVESTMENTS IN SMALL-MOLECULE DEVELOPMENT TO SUPPORT GROWTH
                    TABLE 157 MARKET FOR SMALL MOLECULES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 158 NORTH AMERICA: MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 159 EUROPE: MARKET FOR SMALL MOLECULES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 160 ASIA PACIFIC: MARKET FOR SMALL MOLECULES, BY COUNTRY,  2021–2028 (USD MILLION)
    9.3 MONOCLONAL ANTIBODIES 
           9.3.1 GROWING GOVERNMENT SUPPORT FOR MONOCLONAL ANTIBODIES TO DRIVE MARKET
                    TABLE 161 MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 162 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 163 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 164 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION)
    9.4 VACCINES 
           9.4.1 SHIFTING INDUSTRY FOCUS TOWARD CHRONIC DISEASE TREATMENT TO SLOW MARKET GROWTH
                    FIGURE 43 NUMBER OF CLINICAL TRIALS FOR VACCINES (2020–2023)
                    TABLE 165 MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 166 NORTH AMERICA: MARKET FOR VACCINES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 167 EUROPE: MARKET FOR VACCINES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 168 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY,  2021–2028 (USD MILLION)
    9.5 CELL & GENE THERAPY 
           9.5.1 RISING TREND OF OUTSOURCING TO FAVOR MARKET GROWTH
                    FIGURE 44 ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (2022)
                    TABLE 169 MARKET FOR CELL & GENE THERAPY, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 170 NORTH AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 171 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 172 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
    9.6 OTHER APPLICATIONS 
          TABLE 173 MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 174 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 175 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 176 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
 
10 CLINICAL TRIALS MARKET, BY REGION (Page No. - 183)
     10.1 INTRODUCTION 
             TABLE 177 CLINICAL TRIALS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 45 NORTH AMERICA: CLINICAL TRIALS MARKET SNAPSHOT
                        TABLE 178 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 179 NORTH AMERICA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 180 NORTH AMERICA: MARKET, BY SERVICE TYPE,  2021–2028 (USD MILLION)
                        TABLE 181 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 182 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                        TABLE 183 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 US to hold largest share of North American market over forecast period
                                      FIGURE 46 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023): US TO HOLD DOMINANT SHARE
                                      TABLE 184 US: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 185 US: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 186 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 187 US: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 188 US: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Increasing clinical trial activity to support market growth
                                      TABLE 189 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 190 CANADA: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 191 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 192 CANADA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 193 CANADA: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                        FIGURE 47 PHARMACEUTICAL INDUSTRY R&D SPENDING IN EUROPEAN COUNTRIES,  2021 (USD MILLION)
                        TABLE 194 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 195 EUROPE: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 196 EUROPE: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                        TABLE 197 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 198 EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 199 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Germany to dominate clinical trials market in Europe
                                      TABLE 200 GERMANY: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 201 GERMANY: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 202 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 203 GERMANY: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                                      TABLE 204 GERMANY: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Investments in drug discovery services to support market growth
                                      FIGURE 48 UK: PHARMACEUTICAL R&D EXPENDITURE, 2018–2021 (USD MILLION)
                                      TABLE 205 UK: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 206 UK: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 207 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 208 UK: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 209 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 High number of oncology clinical trials to drive market
                                      TABLE 210 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 211 FRANCE: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 212 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 213 FRANCE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 214 FRANCE: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Low drug approval times and growing number of clinical trials to boost market
                                      TABLE 215 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 216 ITALY: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 217 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 218 ITALY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 219 ITALY: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Rising R&D expenditure to drive market
                                      FIGURE 49 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2018–2021 (USD MILLION)
                                      TABLE 220 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 221 SPAIN: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 222 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 223 SPAIN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 224 SPAIN: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 225 REST OF EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 226 REST OF EUROPE: MARKET, BY SERVICE TYPE,  2021–2028 (USD MILLION)
                        TABLE 227 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 228 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                        TABLE 229 REST OF EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 50 ASIA PACIFIC: CLINICAL TRIALS MARKET SNAPSHOT
                        TABLE 230 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 231 ASIA PACIFIC: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 232 ASIA PACIFIC: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                        TABLE 233 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 234 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                        TABLE 235 ASIA PACIFIC: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 China to dominate APAC clinical trial market
                                      TABLE 236 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 237 CHINA: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 238 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 239 CHINA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 240 CHINA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Strong focus on R&D activities to support growth
                                      FIGURE 51 TOP THERAPEUTIC AREAS OF INDUSTRY-SPONSORED CLINICAL TRIALS IN JAPAN
                                      TABLE 241 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 242 JAPAN: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 243 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 244 JAPAN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 245 JAPAN: CLINICAL TRIALS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Growing pharmaceutical industry to drive market
                                      TABLE 246 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 247 INDIA: MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 248 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 249 INDIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 250 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        FIGURE 52 BREAKDOWN OF STUDIES IN MALAYSIA, BY INTERVENTION, 2021
                        TABLE 251 REST OF ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 252 REST OF ASIA PACIFIC: MARKET, BY SERVICE TYPE,  2021–2028 (USD MILLION)
                        TABLE 253 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 254 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                        TABLE 255 REST OF ASIA PACIFIC: CLINICAL TRIALS INDUSTRY, BY APPLICATION,  2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 RISING PHARMA & BIOTECH R&D TO BOOST MARKET GROWTH
             10.5.2 LATIN AMERICA: RECESSION IMPACT
                        TABLE 256 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 257 LATIN AMERICA: MARKET, BY SERVICE TYPE,  2021–2028 (USD MILLION)
                        TABLE 258 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 259 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                        TABLE 260 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
             10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 261 MIDDLE EAST & AFRICA: CLINICAL TRIALS MARKET, BY PHASE,  2021–2028 (USD MILLION)
                        TABLE 262 MIDDLE EAST & AFRICA: MARKET, BY SERVICE TYPE,  2021–2028 (USD MILLION)
                        TABLE 263 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,  BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 264 MIDDLE EAST & AFRICA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                        TABLE 265 MIDDLE EAST & AFRICA: CLINICAL TRIALS INDUSTRY, BY APPLICATION,  2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 246)
     11.1 INTRODUCTION 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 53 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MARKET PLAYERS
     11.3 REVENUE SHARE ANALYSIS 
             FIGURE 54 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
             TABLE 266 CLINICAL TRIALS MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION MATRIX, 2022 
             FIGURE 56 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2022
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
     11.6 COMPANY FOOTPRINT ANALYSIS OF TOP 25 PLAYERS 
             11.6.1 INDUSTRY FOOTPRINT (25 COMPANIES)
                       TABLE 267 INDUSTRY FOOTPRINT ANALYSIS: KEY PLAYERS
             11.6.2 SERVICE FOOTPRINT (25 COMPANIES)
                       TABLE 268 SERVICE FOOTPRINT ANALYSIS: KEY PLAYERS
             11.6.3 REGIONAL FOOTPRINT (25 COMPANIES)
                       TABLE 269 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
     11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 
             FIGURE 57 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
             11.7.1 PROGRESSIVE COMPANIES
             11.7.2 STARTING BLOCKS
             11.7.3 RESPONSIVE COMPANIES
             11.7.4 DYNAMIC COMPANIES
     11.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 
             TABLE 270 CLINICAL TRIALS INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
             TABLE 271 SERVICE FOOTPRINT ANALYSIS: START-UP/SMES
             TABLE 272 REGIONAL FOOTPRINT ANALYSIS: START-UPS/SMES
     11.9 COMPETITIVE SCENARIO AND TRENDS 
             11.9.1 SERVICE LAUNCHES
                        TABLE 273 CLINICAL TRIALS INDUSTRY: SERVICE LAUNCHES (2020–2023)
             11.9.2 DEALS
                        TABLE 274 CLINICAL TRIALS MARKET: DEALS (2020–2023)
             11.9.3 OTHER DEVELOPMENTS
                        TABLE 275 CLINICAL TRIALS MARKET: OTHER DEVELOPMENTS (2020–2023)
 
12 COMPANY PROFILES (Page No. - 264)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
     12.1 KEY COMPANIES 
             12.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 276 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 58 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
             12.1.2 IQVIA, INC.
                        TABLE 277 IQVIA, INC.: BUSINESS OVERVIEW
                        FIGURE 59 IQVIA, INC.: COMPANY SNAPSHOT
             12.1.3 ICON PLC
                        TABLE 278 ICON PLC: BUSINESS OVERVIEW
                        FIGURE 60 ICON PLC: COMPANY SNAPSHOT
             12.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 279 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 61 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
             12.1.5 SYNEOS HEALTH
                        TABLE 280 SYNEOS HEALTH: BUSINESS OVERVIEW
                        FIGURE 62 SYNEOS HEALTH: COMPANY SNAPSHOT
             12.1.6 WUXI APPTEC
                        TABLE 281 WUXI APPTEC: BUSINESS OVERVIEW
                        FIGURE 63 WUXI APPTEC: COMPANY SNAPSHOT
             12.1.7 CHARLES RIVER LABORATORIES
                        TABLE 282 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 64 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
             12.1.8 PAREXEL INTERNATIONAL CORPORATION
                        TABLE 283 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
             12.1.9 FORTREA, INC.
                        TABLE 284 FORTREA, INC.: BUSINESS OVERVIEW
                        FIGURE 65 FORTREA, INC.: COMPANY SNAPSHOT
             12.1.10 MEDPACE
                        TABLE 285 MEDPACE: BUSINESS OVERVIEW
                        FIGURE 66 MEDPACE: COMPANY SNAPSHOT
             12.1.11 SGS
                        TABLE 286 SGS: BUSINESS OVERVIEW
                        FIGURE 67 SGS: COMPANY SNAPSHOT
             12.1.12 FRONTAGE LABS
                        TABLE 287 FRONTAGE LABS: BUSINESS OVERVIEW
                        FIGURE 68 FRONTAGE LABS: COMPANY SNAPSHOT
             12.1.13 ACM GLOBAL LABORATORIES
                        TABLE 288 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
             12.1.14 ADVANCED CLINICAL
                        TABLE 289 ADVANCED CLINICAL: BUSINESS OVERVIEW
             12.1.15 PSI
                        TABLE 290 PSI: BUSINESS OVERVIEW
             12.1.16 BIOAGILE
                        TABLE 291 BIOAGILE: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 CLINICAL TRIAL SERVICE
             12.2.2 WORLDWIDE CLINICAL TRIALS
             12.2.3 PEPGRA
             12.2.4 CTI CLINICAL TRIAL AND CONSULTING SERVICES
             12.2.5 DOVE QUALITY SOLUTIONS
             12.2.6 FIRMA CLINICAL RESEARCH
             12.2.7 CELERION
             12.2.8 NOVOTECH
             12.2.9 LINICAL AMERICAS
 
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 346)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This research study of the global clinical trials market involved the extensive use of secondary sources, directories, and databases to identify and collect relevant information. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the clinical trials market (estimated through various research approaches) was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the Association of Clinical Research Organization (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICROS), Clinical and Contract Research Association (CCRA), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements), business magazines and research journals, press releases, and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global clinical trials market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global clinical trials market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 40% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Clinical Trials Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the clinical trials market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the clinical trial services business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Market Size Estimation Methodology-bottom-up approach:

Clinical Trials Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Market Size Estimation Methodology-top-down approach:

Clinical Trials Market Size, and Share

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Clinical trial service providers offer research services contractually to pharmaceutical & biotechnology companies, medical device companies, and academic institutes. These services include clinical research, laboratory, consulting, and data management. A sponsor, i.e., a company investigating the safety and efficacy of new drugs, therapies, or medical devices, partners with a CRO on a contractual or project-by-project basis. A CRO provides advice and guidance for the planning, designing, and execution of clinical trials; it offers a comprehensive and diverse range of services for each phase of clinical trials.

Key Stakeholders

  • Contract Research Organizations (CROs)/Clinical Trial Service Providers
  • Pharmaceutical and Biopharmaceutical Companies
  • Medical Device Manufacturing Companies
  • Academic and Research Institutes
  • Venture Capitalists and Investors
  • Market Research and Consulting Firms
  • Government Associations
  • Medical Institutions and Universities

Report Objectives

  • To define, describe, and forecast the clinical trials market based on phase, service type, therapy area, application, and region.
  • To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
  • To strategically analyze micro markets concerning their growth trends, prospects, and contributions to the total clinical trials market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the revenue of market segments in five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies.
  • To track and analyze competitive developments in the clinical trials market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and R&D activities.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the Rest of Europe's clinical trials market, by country
  • Further breakdown of the Rest of Asia Pacific clinical trials market, by country
  • Further breakdown of the Latin American Middle Eastern & African clinical trials markets, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Further breakdown of the therapeutic area segment as per the service portfolios of prominent players operating in the market.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 1622
Published ON
Sep, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Clinical Trials Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback